Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different
ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies
such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing
substances to them without harming normal cells. Bevacizumab may also stop the growth of
tumor cells by stopping blood flow to the tumor. Combining chemotherapy with monoclonal
antibody therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel and capecitabine together
with bevacizumab works in treating patients with metastatic breast cancer.